CoChat

Targeting bile‐acid signalling for metabolic diseases

Open access

The DOI matches its Crossref record; 165 of the 169 references it cites were found in a registry or an index.

Abstract

Bile acids are increasingly being appreciated as complex metabolic integrators and signalling factors and not just as lipid solubilizers and simple regulators of bile-acid homeostasis. It is therefore not surprising that a number of bile-acid-activated signalling pathways have become attractive therapeutic targets for metabolic disorders. Here, we review how the signalling functions of bile acids can be exploited in the development of drugs for obesity, type 2 diabetes, hypertriglyceridaemia and atherosclerosis, as well as other associated chronic diseases such as non-alcoholic steatohepatitis.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd2619

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 165 references

Research works printed but not linked: 1

  1. Harnish, D. C. et al. A synthetic farnesoid X receptor (FXR) agonist protects against diet-induced dyslipidemia. J. Clin. Lipidol. 1, 362 (2007).

Cited by

Items 101–200 of 1,002

Metadata

Authors
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K.
Affiliations
  • Institut de génétique et de biologie moléculaire et cellulaire (FR)
  • University of Perugia (IT)
  • Intercept Pharmaceuticals (United States) (US)
Corresponding author
  • Auwerx, Johan
  • Schoonjans, Kristina
Venue
Nature Reviews Drug Discovery
Published
2008-08
Volume
7
Issue
8
Pages
678-693
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2078810890
Cited by
1,422
References
169
Citations by year
2026: 81 · 2025: 92 · 2024: 106 · 2023: 107 · 2022: 113 · 2021: 90 · 2020: 83 · 2019: 82 · 2018: 78 · 2017: 81 · 2016: 75 · 2015: 75 · 2014: 71 · 2013: 77 · 2012: 47
FWCI
5.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Funders
  • European Commission
  • Institut National de la Santé et de la Recherche Médicale
  • Fondation pour la Recherche Médicale
  • Ligue Contre le Cancer
  • Centre National de la Recherche Scientifique
  • Société Française de Nutrition
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
Keywords
bile acids, bile acid signaling, metabolic disorders, obesity, type 2 diabetes, hypertriglyceridemia, atherosclerosis, nonalcoholic steatohepatitis, therapeutic target, drug development
MeSH terms
Animals, Bile Acids and Salts, Humans, Metabolic Diseases, Signal Transduction, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.